Talis Wins Up-to-$8.6M from CARB-X to Develop MDx for Infectious Diseases
Summary
Talis Biomedical has won up to $8.6 million from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) toward developing a pair of rapid molecular diagnostic tests for infectious diseases. By combining proprietary isothermal amplification chemistries, original engineering, and data science tools, Talis says its platform allows users to load sample, walk away, and review results remotely. Results from the initial collaboration with Talis were detailed in “Rapid pathogen-specific phenotypic antibiotic susceptibility testing using digital LAMP quantification in clinical samples.” In the study, published online in October 2017 in Science Translational Medicine, Dr. Ismagilov and colleagues carried out antimicrobial susceptibility testing via digital nucleic acid quantification to measure the phenotypic response of Escherichia coli present within clinical urine samples exposed to an antibiotic for 15 minutes. They found that dLAMP can be used with SlipChip microfluidic devices to determine the phenotypic antibiotic susceptibility of E. coli directly from clinical urine samples in less than 30 minutes. “Talis Biomedicals project could potentially speed up and improve the way drug-resistant gonorrhea and other serious diseases are diagnosed and treated,” CARB-X Executive Director Kevin Outterson stated.
Classifications
AskAI Classifications
LabelsLinked Companies
